Kenneth C. Frazier is Chairman of the Board and Chief Executive Officer of Merck & Co., Inc.

Under Mr. Frazier’s leadership, Merck is delivering innovative lifesaving medicines and vaccines as well as long-term and sustainable value to its multiple stakeholders. Mr. Frazier has substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide benefit to society. He has also led the formation of philanthropic and other initiatives that build on Merck’s 125-year plus legacy.

Mr. Frazier joined the company in 1992 as Vice President, General Counsel and Secretary of the company’s joint venture with Astra AB. He became Vice President of Public Affairs in 1994, and in 1997, was also named Assistant General Counsel. In 1999, Mr. Frazier was promoted to General Counsel of Merck. From 2007 to 2010, he served as President of Global Human Health, Merck’s sales and marketing division. In 2010, Mr. Frazier became President of Merck. He was appointed CEO and a member of Merck’s Board of Directors in January 2011 and became Chairman of the Board in December 2011.

Prior to joining Merck, Mr. Frazier was a partner with the Philadelphia law firm of Drinker Biddle & Reath. He sits on the boards of PhRMA, Weill Cornell Medicine, Exxon Mobil Corporation, and Cornerstone Christian Academy in Philadelphia, PA. He also is a member of the American Academy of Arts and Sciences, The Business Council, the Council of the American Law Institute, and the American Bar Association.

Mr. Frazier received his bachelor’s degree from The Pennsylvania State University and holds a J.D. from Harvard Law School.

# # #

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through Merck’s prescription medicines, vaccines, biologic therapies and animal health products, the company works with customers and operates in more than 140 countries to deliver innovative health solutions. Merck also demonstrates our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases, including HIV and Ebola. For more information, visit www.merck.com and connect with Merck on Twitter, Facebook, YouTube and LinkedIn.

January 2018